Santarus Inc. Announces Presentation of Phase III Data for Rifamycin SV MMX in Travelers’ Diarrhea

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Santarus, Inc. (NASDAQ:SNTS) today announced that new data from its Phase III clinical study with the investigational drug rifamycin SV MMX® in patients with travelers’ diarrhea will be featured in a poster presentation at IDWeek™ in San Francisco at the Moscone Center (Poster Hall C) from 12:30 p.m. to 2:00 p.m. Pacific Time on Saturday, October 5, 2013. Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC